ABSTRACT
Abstract This study aimed to detect, quantify and compare the immunohistochemical expression of EGFR and VEGF and microvessel count (MVC) in oral lipomas, and to correlate the findings with clinical and morphological characteristics of the cases studied. The sample consisted of 54 oral lipomas (33 classic and 21 non-classic) and 23 normal adipose tissue specimens. Cytoplasmic and/or nuclear immunohistochemical staining of EGFR and VEGF was analyzed. The angiogenic index was determined by MVC. Cells were counted using the Image J® software. The Statistical Package for the Social Sciences was used for data analysis, adopting a level of significance of 5% for all statistical tests. A statistically significant difference in EGFR immunoexpression (p=0.047), especially, between classic lipomas and normal adipose tissue. There was a significant difference in MVC between non-classic lipomas and normal adipose tissue (p=0.022). In non-classic lipomas, only VEGF immunoexpression showed a significant moderate positive correlation (r=0.607, p=0.01) with MVC. In classic lipomas, the number of EGFR-immunostained adipocytes was directly proportional to the number of VEGF-positive cells, demonstrating a significant moderate positive correlation (r=0.566, p=0.005). The results suggest that EGFR, VEGF, and angiogenesis participate in the development of oral lipomas but are not primarily involved in the growth of these tumors.
Resumo Lipomas são as neoplasias mesenquimais benignas mais comuns, no entanto sua etiopatogenia ainda permanece desconhecida. Dessa forma, essa pesquisa teve como objetivo detectar, quantificar e comparar a expressão imunoistoquímica do EGFR, VEGF e contagem microvascular (MVC) dos lipomas orais, relacionando-os com as características clínicas e morfológicas dos casos estudados. A amostra foi composta por 54 lipomas orais (33 clássicos e 21 não clássicos) e 23 casos de tecido adiposo normal. A análise da expressão imunoistoquímica de EGFR e VEGF foi fundamentada na marcação citoplasmática e/ou nuclear. O índice angiogênico foi avaliado por meio da MVC. A contagem de células foi realizada utilizando software IMAGE J®. Os dados obtidos foram analisados no software Statistical Package for Social Science. O nível se significância de 5% foi adotado para os testes estatístico. A análise da imunoexpressão das proteínas revelou para o EGFR diferença estatisticamente significativa (p=0,041) entre o lipoma clássico e o tecido adiposo normal. Houve diferença significativa na MVC entre lipomas não clássicos e tecido adiposo normal (p=0,022). Nos lipomas não clássicos, apenas a imunoexpressão de VEGF apresentou correlação do tipo moderada, positiva e significativa (r=0,607; p=0,010) em relação a MVC. Ademais, nos lipomas clássicos foi percebido que os adipócitos imunomarcados para EGFR estiveram diretamente proporcionais a imunoexpressão de VEGF, apresentando correlação do tipo moderada, positiva e estatisticamente significativa (r=0,566; p = 0,005). Com base nos resultados, pode-se sugerir que o EGFR, VEGFR e MCV participam do desenvolvimento nos lipomas orais, contudo, não estão primariamente envolvidos no crescimento tumoral dessas neoplasias.
ABSTRACT
BACKGROUND: The major challenge for obstetrics is the prediction and prevention of the great obstetrical syndromes. We propose that defining obstetrical diseases by the combination of clinical presentation and disease mechanisms as inferred by placental pathology will aid in the discovery of biomarkers and add specificity to those already known. OBJECTIVE: To describe the longitudinal profile of placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and the PlGF/sFlt-1 ratio throughout gestation, and to determine whether the association between abnormal biomarker profiles and obstetrical syndromes is strengthened by information derived from placental examination, eg, the presence or absence of placental lesions of maternal vascular malperfusion. STUDY DESIGN: This retrospective case cohort study was based on a parent cohort of 4006 pregnant women enrolled prospectively. The case cohort of 1499 pregnant women included 1000 randomly selected patients from the parent cohort and all additional patients with obstetrical syndromes from the parent cohort. Pregnant women were classified into six groups: 1) term delivery without pregnancy complications (n=540; control); 2) preterm labor and delivery (n=203); 3) preterm premature rupture of the membranes (n=112); 4) preeclampsia (n=230); 5) small-for-gestational-age neonate (n=334); and 6) other pregnancy complications (n=182). Maternal plasma concentrations of PlGF and sFlt-1 were determined by enzyme-linked immunosorbent assays in 7560 longitudinal samples. Placental pathologists, masked to clinical outcomes, diagnosed the presence or absence of placental lesions of maternal vascular malperfusion. Comparisons between mean biomarker concentrations in cases and controls were performed by utilizing longitudinal generalized additive models. Comparisons were made between controls and each obstetrical syndrome with and without subclassifying cases according to the presence or absence of placental lesions of maternal vascular malperfusion. RESULTS: 1) When obstetrical syndromes are classified based on the presence or absence of placental lesions of maternal vascular malperfusion, significant differences in the mean plasma concentrations of PlGF, sFlt-1, and the PlGF/sFlt-1 ratio between cases and controls emerge earlier in gestation; 2) the strength of association between an abnormal PlGF/sFlt-1 ratio and the occurrence of obstetrical syndromes increases when placental lesions of maternal vascular malperfusion are present (adjusted odds ratio [aOR], 13.6 vs 6.7 for preeclampsia; aOR, 8.1 vs 4.4 for small-for-gestational-age neonates; aOR, 5.5 vs 2.1 for preterm premature rupture of the membranes; and aOR, 3.3 vs 2.1 for preterm labor (all P<0.05); and 3) the PlGF/sFlt-1 ratio at 28 to 32 weeks of gestation is abnormal in patients who subsequently delivered due to preterm labor with intact membranes and in those with preterm premature rupture of the membranes if both groups have placental lesions of maternal vascular malperfusion. Such association is not significant in patients with these obstetrical syndromes who do not have placental lesions. CONCLUSION: Classification of obstetrical syndromes according to the presence or absence of placental lesions of maternal vascular malperfusion allows biomarkers to be informative earlier in gestation and enhances the strength of association between biomarkers and clinical outcomes. We propose that a new taxonomy of obstetrical disorders informed by placental pathology will facilitate the discovery and implementation of biomarkers as well as the prediction and prevention of such disorders.
Subject(s)
Obstetric Labor Complications , Obstetric Labor, Premature , Pre-Eclampsia , Biomarkers , Cohort Studies , Female , Fetal Membranes, Premature Rupture , Humans , Infant, Newborn , Placenta/pathology , Placenta Growth Factor , Pregnancy , Retrospective Studies , Vascular Endothelial Growth Factor Receptor-1ABSTRACT
Lipomas são as neoplasias mesênquimais benignas mais comuns. Apresentam predileção pelo tronco, ombros, pescoço e axila, sendo raro nas mãos, parte inferior das pernas e pés. A região de cabeça e pescoço é responsável por 20% dos casos. A cavidade oral é responsável por 1-4% de todos os tumores, afeta de maneira semelhante o sexo feminino e masculino, acometendo ampla faixa etária. A etiopatogênia desse tumor ainda permanece desconhecida, dessa forma, essa pesquisa teve como objetivo detectar, quantificar e comparar a expressão imunoistoquímica do EGFR, VEGF e contagem microvascular (MVC) dos lipomas orais, relacionando-os com as características clínicas e morfológicas dos casos estudados. A amostra foi composta por 54 lipomas orais (33 clássicos e 21 não clássicos) e 23 casos de tecido adiposo normal. A análise da expressão imunoistoquímica de EGFR e VEGF foi fundamentada na marcação da membrana citoplasmática e/ou núcleo. O índice angiogênico foi avaliado por meio da contagem microvascular (MVC). A contagem de células foi realizada utilizando software IMAGE J®. Os dados obtidos foram analisados no software Statistical Package for Social Science. O nível se significância de 5% foi adotado para os testes estatísticos (p ≤ 0,05). A Análise da imunoexpressão das proteínas revelou para o EGFR diferença estatisticamente significativa (p=0,041) entre o lipoma clássico e o tecido adiposo normal. Com relação a contagem de microvasos, o CMV dos lipomas não clássico apresentou diferença estatisticamente significativa (p=0,018) em relação ao tecido adiposo normal. Nos lipomas não clássicos, apenas a imunoexpressão de VEGF esteve diretamente proporcional a CMV encontrado na neoplasia, com correlação do tipo moderada, positiva e significativa (p=0,010). Ademais, nos lipomas clássicos foi percebido que os adipócitos imunomarcados para EGFR estiveram diretamente proporcionais a imunoexpressão de VEGF, isso deve-se a correlação do tipo moderada, positiva e estatisticamente significativa (p = 0,005). Com base nos resultados, pode-se concluir que apesar do EGFR, VEGFR e CMV participarem do desenvolvimento neoplásico, é possível sugerir que nos lipomas, essas proteínas e o CMV não estejam primariamente envolvidos no crescimento tumoral (AU).
Lipomas are the most common benign mesenchymal neoplasms. They have a predilection for the trunk, shoulders, neck and armpit, being rare in the hands, lower legs and feet. The head and neck region accounts for 20% of cases. The oral cavity is responsible for 1-4% of all tumors, affecting females and males in a similar way, affecting a wide age range. The etiopathogenesis of this tumor remains unknown, therefore, this research aimed to detect, quantify and compare the immunohistochemical expression of EGFR, VEGF and microvascular count (MVC) of oral lipomas, relating them to the clinical and morphological characteristics of the cases studied . The sample consisted of 54 oral lipomas (33 classic and 21 non-classical) and 23 cases of normal adipose tissue. The analysis of the immunohistochemical expression of EGFR and VEGF was based on cytoplasmic membrane and/or nucleus labeling. The angiogenic index was assessed using microvascular count (MVC). Cell counting was performed using IMAGE J® software. The data obtained were analyzed using the Statistical Package for Social Science software. A significance level of 5% was adopted for statistical tests (p ≤ 0.05). Analysis of protein immunoexpression revealed a statistically significant difference (p=0.041) for EGFR between classic lipoma and normal adipose tissue. Regarding microvessel count, the CMV of non-classic lipomas showed a statistically significant difference (p=0.018) in relation to normal adipose tissue. In non-classical lipomas, only VEGF immunoexpression was directly proportional to the CMV found in the neoplasm, with a moderate, positive and significant correlation (p=0.010). Furthermore, in classical lipomas it was noticed that adipocytes immunolabeled for EGFR were directly proportional to VEGF immunoexpression, this is due to the moderate, positive and statistically significant correlation (p = 0.005). Based on the results, it can be concluded that although EGFR, VEGFR and CMV participate in neoplastic development, it is possible to suggest that in lipomas, these proteins and CMV are not primarily involved in tumor growth (AU).
Subject(s)
Receptors, Growth Factor , Lipoma/diagnosis , Lipoma/metabolism , Neovascularization, Pathologic/pathology , Mouth Neoplasms/pathology , Cross-Sectional Studies/methods , Statistics, Nonparametric , Vascular Endothelial Growth Factor AABSTRACT
Angiogenesis is a crucial process in the development of inflammatory diseases, including cancer, psoriasis and rheumatoid arthritis. Recently, several alkaloids from Picrasma quassioides had been screened for angiogenic activity in the zebrafish model, and the results indicated that 1-methoxycarbony-ß-carboline (MCC) could effectively inhibit blood vessel formation. In this study, we further confirmed that MCC can inhibit, in a concentration-dependent manner, the viability, migration, invasion, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro, as well as the regenerative vascular outgrowth of zebrafish caudal fin in vivo. In the zebrafish xenograft assay, MCC inhibited the growth of tumor masses and the metastatic transplanted DU145 tumor cells. The proteome profile array of the MCC-treated HUVECs showed that MCC could down-regulate several angiogenesis-related self-secreted proteins, including ANG, EGF, bFGF, GRO, IGF-1, PLG and MMP-1. In addition, the expression of two key membrane receptor proteins in angiogenesis, TIE-2 and uPAR, were also down-regulated after MCC treatment. Taken together, these results shed light on the potential therapeutic application of MCC as a potent natural angiogenesis inhibitor via multiple molecular targets.
Subject(s)
Angiogenesis Inhibitors/pharmacology , Carbolines/pharmacology , Human Umbilical Vein Endothelial Cells/drug effects , Neovascularization, Physiologic/drug effects , Picrasma/chemistry , Plant Extracts/pharmacology , Zebrafish/embryology , Angiogenesis Inhibitors/chemistry , Animals , Carbolines/chemistry , Cell Movement/drug effects , Cell Proliferation/drug effects , Epidermal Growth Factor/genetics , Epidermal Growth Factor/metabolism , Fibroblast Growth Factors/genetics , Fibroblast Growth Factors/metabolism , Human Umbilical Vein Endothelial Cells/cytology , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor I/metabolism , Plant Extracts/chemistry , Receptor, TIE-2/genetics , Receptor, TIE-2/metabolismABSTRACT
Angiogenesis is a crucial process in the development of inflammatory diseases, including cancer, psoriasis and rheumatoid arthritis. Recently, several alkaloids from Picrasma quassioides had been screened for angiogenic activity in the zebrafish model, and the results indicated that 1-methoxycarbony-β-carboline (MCC) could effectively inhibit blood vessel formation. In this study, we further confirmed that MCC can inhibit, in a concentration-dependent manner, the viability, migration, invasion, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro, as well as the regenerative vascular outgrowth of zebrafish caudal fin in vivo. In the zebrafish xenograft assay, MCC inhibited the growth of tumor masses and the metastatic transplanted DU145 tumor cells. The proteome profile array of the MCC-treated HUVECs showed that MCC could down-regulate several angiogenesis-related self-secreted proteins, including ANG, EGF, bFGF, GRO, IGF-1, PLG and MMP-1. In addition, the expression of two key membrane receptor proteins in angiogenesis, TIE-2 and uPAR, were also down-regulated after MCC treatment. Taken together, these results shed light on the potential therapeutic application of MCC as a potent natural angiogenesis inhibitor via multiple molecular targets.
Subject(s)
Animals , Humans , Angiogenesis Inhibitors , Chemistry , Pharmacology , Carbolines , Chemistry , Pharmacology , Cell Movement , Cell Proliferation , Epidermal Growth Factor , Genetics , Metabolism , Fibroblast Growth Factors , Genetics , Metabolism , Human Umbilical Vein Endothelial Cells , Cell Biology , Metabolism , Insulin-Like Growth Factor I , Genetics , Metabolism , Neovascularization, Physiologic , Picrasma , Chemistry , Plant Extracts , Chemistry , Pharmacology , Receptor, TIE-2 , Genetics , Metabolism , Zebrafish , EmbryologyABSTRACT
Angiogenesis is a crucial process in the development of inflammatory diseases, including cancer, psoriasis and rheumatoid arthritis. Recently, several alkaloids from Picrasma quassioides had been screened for angiogenic activity in the zebrafish model, and the results indicated that 1-methoxycarbony-β-carboline (MCC) could effectively inhibit blood vessel formation. In this study, we further confirmed that MCC can inhibit, in a concentration-dependent manner, the viability, migration, invasion, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro, as well as the regenerative vascular outgrowth of zebrafish caudal fin in vivo. In the zebrafish xenograft assay, MCC inhibited the growth of tumor masses and the metastatic transplanted DU145 tumor cells. The proteome profile array of the MCC-treated HUVECs showed that MCC could down-regulate several angiogenesis-related self-secreted proteins, including ANG, EGF, bFGF, GRO, IGF-1, PLG and MMP-1. In addition, the expression of two key membrane receptor proteins in angiogenesis, TIE-2 and uPAR, were also down-regulated after MCC treatment. Taken together, these results shed light on the potential therapeutic application of MCC as a potent natural angiogenesis inhibitor via multiple molecular targets.
Subject(s)
Animals , Humans , Angiogenesis Inhibitors , Chemistry , Pharmacology , Carbolines , Chemistry , Pharmacology , Cell Movement , Cell Proliferation , Epidermal Growth Factor , Genetics , Metabolism , Fibroblast Growth Factors , Genetics , Metabolism , Human Umbilical Vein Endothelial Cells , Cell Biology , Metabolism , Insulin-Like Growth Factor I , Genetics , Metabolism , Neovascularization, Physiologic , Picrasma , Chemistry , Plant Extracts , Chemistry , Pharmacology , Receptor, TIE-2 , Genetics , Metabolism , Zebrafish , EmbryologyABSTRACT
This study aimed to evaluate and compare the immunoexpression of glucose transporter-1 (GLUT-1) and angiogenic index between pleomorphic adenomas (PAs), adenoid cystic carcinomas (ACCs), and mucoepidermoid carcinomas (MECs) of the salivary glands, and establish associations with the respective subtype/histological grade. Twenty PAs, 20 ACCs, and 10 MECs were submitted to morphological and immunohistochemical analysis. GLUT-1 expression was semi-quantitatively evaluated and angiogenic index was assessed by microvessel counts using anti-CD34 antibody. Higher GLUT-1 immunoexpression was observed in the MECs compared to PAs and ACCs (p = 0.022). Mean number of microvessels was 66.5 in MECs, 40.4 in PAs, and 21.2 in ACCs (p < 0.001). GLUT-1 expression and angiogenic index showed no significant correlation in the tumors studied. Results suggest that differences in biological behavior of the studied tumors are related to GLUT-1. Benign and malignant salivary gland tumors differ in the angiogenic index; however, angiogenesis may be independent of the tumor cell's metabolic demand.
Subject(s)
Adenoma, Pleomorphic/metabolism , Carcinoma, Adenoid Cystic/metabolism , Carcinoma, Mucoepidermoid/metabolism , Excitatory Amino Acid Transporter 2/metabolism , Neovascularization, Pathologic , Salivary Gland Neoplasms/metabolism , Adenoma, Pleomorphic/blood supply , Adenoma, Pleomorphic/pathology , Biomarkers, Tumor/metabolism , Carcinoma, Adenoid Cystic/blood supply , Carcinoma, Adenoid Cystic/pathology , Carcinoma, Mucoepidermoid/blood supply , Carcinoma, Mucoepidermoid/pathology , Female , Humans , Immunohistochemistry , Male , Microvessels/pathology , Middle Aged , Neoplasm Grading , Salivary Gland Neoplasms/blood supply , Salivary Gland Neoplasms/pathology , Salivary Glands/pathologyABSTRACT
A expressão da proteína transportadora de glicose tipo 1 (GLUT-1), bem como a angiogênese, têm sido relacionadas ao comportamento clínico e agressividade em neoplasias de origem diversas. Acredita-se que a expressão desta proteína denote a demanda metabólica das células tumorais e, assim, a sua influência na formação de novos vasos sanguineos. O adenoma pleomórfico (AP) e o carcinoma adenoide cístico (CAC) e carcinoma mucoepidermóide (CME) representam, respectivamente, a neoplasia benigna e as malignas mais frequentes das glândulas salivares. O propósito deste estudo foi comparar a expressão imuno-histoquímica da GLUT-1, bem como correlacionar com a angiogênese em casos de APs, CACs e CMEs levando em consideração suas gradações histológicas. A amostra foi composta por 20 APs, 20 CACs e 10 CMEs os quais foram classificados de acordo com os graus histológicos apresentados. A expressão da GLUT-1 foi avaliada no parênquima das lesões, estabelecendo-se o percentual de células imunopositivas, de acordo com os escores: 0 (nenhuma célula imunomarcada), 1 (até 25% das células tumorais imunomarcadas), 2 (de 25- 50% das células tumorais imunomarcadas) e 3 (mais de 50% das células tumorais imunomarcadas). O índice angiogênico foi analisado por meio da contagem de microvasos imunomarcados pelo anticorpo anti-CD34, em 5 campos (200x). A análise da expressão da GLUT-1 revelou diferenças estatisticamente significativas entre os grupos benignos e malignos (p = 0,022). O número médio de microvasos foi de 40,4 em APs, 21,2 em CACs e 66,5 em CMEs, com diferenças significativas entre os grupos (p < 0,001). Quando comparadas a expressão da GLUT-1 com o índice angiogênico em conjunto, não foi evidenciada correlação significativa entre a quantidade de microvasos e a expressão da GLUT-1 (r = 0,211; p = 0,141). Os resultados do presente estudo sugerem que as diferenças no comportamento biológico entre APs, CACs e CMEs podem estar relacionadas à expressão da GLUT-1 e que tumores benignos e malignos de glândulas salivares exibem diferenças no número médio de microvasos, com maiores índices nos tumores considerados mais agressivos. Além disto, o número de microvasos neoformados pode ser independente da demanda metabólica das células tumorais. (AU)
The expression of glucose transporter protein 1 (GLUT-1), as well the angiogenesis has been associated to clinical behavior and aggressiveness in tumors of various origin. It is believed that the expression of this protein denotes metabolic demand of the tumor cells and, thus its influence upon the formation of new blood vessels. Pleomorphic adenoma (PA) and the adenoid cystic carcinoma (ACC) and mucoepidermoid carcinoma (MEC) represent, respectively, the most commom benign and malignant tumors of salivary glands. The aim of this study was to analyze and compare the immunohistochemical expression of GLUT-1 and its correlation with angiogenesis in cases of PAs, ACCs and MECs considering their histological grades. The sample consisted of 20 PAs, 20 ACCs and 10 MECs. The cases were analyzed and classified according to their histological grades. The expression of GLUT-1 was evaluated in the parenchyma lesions, establishing the percentage of immunopositive cells, according to the following scores: 0 (no cell immunomarked), 1 (up to 25% of tumor cells immunostained), 2 (25 - 50% of tumor cells immunostained) and 3 (more than 50% of tumor cells immunostained). The angiogenic index was analyzed by counting the microvessels immunostained by anti-CD34 antibody, in 5 fields (200X). The analysis of the expression of GLUT-1 in tumor parenchyma showed statistically significant differences between benign and malignant groups (p = 0.022). The average number of microvessels in PAs was 40.4, 21.2 in ACCs and 66.5 in MECs, with significant differences between groups (p <0.001). When compared to the expression of GLUT-1 and angiogenic index as a whole, there was no significant correlation between the number of microvessels and the expression of GLUT-1 (r = 0.211, p = 0.141). In conclusion, the results of this study suggest not only that differences in biological behavior between PAs, ACCs and MECs may be associated to the expression of GLUT-1, but also that benign and malignant salivary gland present differences in the average number of microvessels, with higher levels considered more aggressive tumors. Furthermore, the number of newly formed microvessels can be independent of the metabolic demand of the tumor cells. (AU)
